These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1578705)

  • 21. Another antibody in myasthenia gravis sera?
    McCann J
    JAMA; 1982 Mar; 247(9):1237. PubMed ID: 7062534
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of antenatal myasthenia gravis.
    Carr SR; Gilchrist JM; Abuelo DN; Clark D
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):485-9. PubMed ID: 1870801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis.
    Yeh JH; Chen WH; Chiu HC; Bai CH
    J Neurol Sci; 2007 Dec; 263(1-2):191-3. PubMed ID: 17602704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myasthenia gravis: a model disorder of acetylcholine receptors.
    Drachman DB
    Res Publ Assoc Res Nerv Ment Dis; 1987; 65():65-82. PubMed ID: 3330842
    [No Abstract]   [Full Text] [Related]  

  • 25. [Antibodies to acetylcholine receptor. Diagnosis and therapeutic interest in myasthenia gravis (author's transl)].
    de Crousaz G
    Ann Chir; 1980 Mar; 34(3):188-92. PubMed ID: 7369693
    [No Abstract]   [Full Text] [Related]  

  • 26. Myasthenia gravis: a clinical review.
    Burke WJ
    Clin Exp Neurol; 1981; 17():1-14. PubMed ID: 7346191
    [No Abstract]   [Full Text] [Related]  

  • 27. [Ocular myasthenia: a diagnostic and management challenge--a review].
    Langmann A; Lindner S; Koch M; Diez J
    Klin Monbl Augenheilkd; 2004 Feb; 221(2):77-86. PubMed ID: 14986204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myasthenia gravis: an example of receptor disease.
    Conti-Tronconi BM; Fumagalli G; Scotti A; Brigonzi A; Sher E; Morgutti M; Clementi F
    Adv Biochem Psychopharmacol; 1980; 21():473-88. PubMed ID: 7376974
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunosorbent treatment in myasthenia gravis.
    Passalacqua S; Splendiani G; Sturniolo A; Costanzi S; Barbera G; Bartoccioni E; Evoli A; Scoppetta C; Adorno D; Di Guilio S
    Prog Clin Biol Res; 1990; 337():285-8. PubMed ID: 2191321
    [No Abstract]   [Full Text] [Related]  

  • 30. Myasthenia gravis patients with anti-MuSK antibodies.
    Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
    Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MuSK-antibody positive myasthenia gravis: questions from the clinic.
    Sanders DB; Juel VC
    J Neuroimmunol; 2008 Sep; 201-202():85-9. PubMed ID: 18684517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of plasma exchange in management of myasthenia gravis (author's transl)].
    Arahata K; Sato T; Narabayashi H
    Rinsho Shinkeigaku; 1981 Jul; 21(7):597-606. PubMed ID: 7307400
    [No Abstract]   [Full Text] [Related]  

  • 34. [Myasthenia gravis and its immunological aspects].
    Kinoshita M; Okada S; Oyamatu T; Iguchi H
    No To Shinkei; 1993 Oct; 45(10):909-16. PubMed ID: 8268030
    [No Abstract]   [Full Text] [Related]  

  • 35. [Myasthenia gravis and neurotransmitters].
    Arimori S
    Nihon Rinsho; 1984 Apr; 42(4):844-9. PubMed ID: 6481980
    [No Abstract]   [Full Text] [Related]  

  • 36. Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient.
    Schlesinger I; Rabinowitz R; Brenner T; Abramsky O; Schlesinger M
    Neurology; 1992 Nov; 42(11):2153-7. PubMed ID: 1436527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Favorable results of plasmapheresis in severe myasthenia gravis].
    Sybesma JP; Hertzberger LI
    Ned Tijdschr Geneeskd; 1997 Apr; 141(17):844-5. PubMed ID: 9221369
    [No Abstract]   [Full Text] [Related]  

  • 38. Autoimmune aspects of myasthenia gravis.
    Lisak RP; Levinson AI; Zweiman B
    Concepts Immunopathol; 1985; 2():65-101. PubMed ID: 3916415
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical study of double filtration plasmapheresis for treatment of refractory myasthenia gravis].
    Huo JT; Long HL; Luo X; Xu JZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):355-7. PubMed ID: 17425991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of plasmapheresis in myasthenia gravis 1978-1980.
    Olarte MR; Schoenfeldt RS; Penn AS; Lovelace RE; Rowland LP
    Ann N Y Acad Sci; 1981; 377():725-8. PubMed ID: 6951496
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.